Cargando…
Serum levels of irisin and nesfatin-1 in multiple sclerosis
BACKGROUND: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. OBJECTIVE: The present study is a preli...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia -ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648912/ https://www.ncbi.nlm.nih.gov/pubmed/35195223 http://dx.doi.org/10.1590/0004-282X-ANP-2020-0520 |
_version_ | 1784827682823864320 |
---|---|
author | ALTAŞ, Mustafa UCA, Ali Ulvi AKDAĞ, Turan ODABAŞ, Faruk Ömer TOKGÖZ, Osman Serhat |
author_facet | ALTAŞ, Mustafa UCA, Ali Ulvi AKDAĞ, Turan ODABAŞ, Faruk Ömer TOKGÖZ, Osman Serhat |
author_sort | ALTAŞ, Mustafa |
collection | PubMed |
description | BACKGROUND: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. OBJECTIVE: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing-remitting MS (RRMS). METHODS: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. RESULTS: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. CONCLUSION: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis. |
format | Online Article Text |
id | pubmed-9648912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academia Brasileira de Neurologia -ABNEURO |
record_format | MEDLINE/PubMed |
spelling | pubmed-96489122022-12-08 Serum levels of irisin and nesfatin-1 in multiple sclerosis ALTAŞ, Mustafa UCA, Ali Ulvi AKDAĞ, Turan ODABAŞ, Faruk Ömer TOKGÖZ, Osman Serhat Arq Neuropsiquiatr Articles BACKGROUND: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. OBJECTIVE: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing-remitting MS (RRMS). METHODS: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. RESULTS: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. CONCLUSION: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis. Academia Brasileira de Neurologia -ABNEURO 2022-02-06 /pmc/articles/PMC9648912/ /pubmed/35195223 http://dx.doi.org/10.1590/0004-282X-ANP-2020-0520 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Articles ALTAŞ, Mustafa UCA, Ali Ulvi AKDAĞ, Turan ODABAŞ, Faruk Ömer TOKGÖZ, Osman Serhat Serum levels of irisin and nesfatin-1 in multiple sclerosis |
title | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
title_full | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
title_fullStr | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
title_full_unstemmed | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
title_short | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
title_sort | serum levels of irisin and nesfatin-1 in multiple sclerosis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648912/ https://www.ncbi.nlm.nih.gov/pubmed/35195223 http://dx.doi.org/10.1590/0004-282X-ANP-2020-0520 |
work_keys_str_mv | AT altasmustafa serumlevelsofirisinandnesfatin1inmultiplesclerosis AT ucaaliulvi serumlevelsofirisinandnesfatin1inmultiplesclerosis AT akdagturan serumlevelsofirisinandnesfatin1inmultiplesclerosis AT odabasfarukomer serumlevelsofirisinandnesfatin1inmultiplesclerosis AT tokgozosmanserhat serumlevelsofirisinandnesfatin1inmultiplesclerosis |